Company profile
Artiva Biotherapeutics, Inc.
NASDAQ: ARTV · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
41DFH 48DQ 29GM —SS 49
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, market scale · ↓ revenue growth (YoY), Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$83.9M
Employees
106
as of 2026-08-13
Market cap
$563.7M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$83.9M-$83.9M2025
Operating income-$89.8M-$89.8M2025
Total assets$130.9M$130.9M2025
Liabilities$21.0M$21.0M2025
Equity$110.0M$110.0M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Artiva Biotherapeutics, Inc.’s revenue?
Artiva Biotherapeutics, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Allogene Therapeutics, Inc.39DAchieve Life Sciences, Inc.37DNeurogene Inc.43DContineum Therapeutics, Inc.57CNika Pharmaceuticals Inc.29DBenitec Biopharma Inc.47DNeighbors
San Diego →Key facts
CEOFred Aslan
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: ARTV
Employees106
IPO date2024-07-19
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.